Our Services
Medical Information
Helpful Resources
Published on: 4/24/2026
Wegovy often leads to diarrhea because as a GLP-1 receptor agonist it slows gastric emptying, increases intestinal fluid secretion, alters gut motility, and may shift your microbiota. Most mild cases improve with dietary tweaks, gradual dose increases, hydration, and short-term use of anti-diarrheals or probiotics.
If diarrhea is severe, persistent, or threatens your weight-loss goals, you may need to consider alternative medications or dosage strategies, so see below for more details.
Wegovy (semaglutide) has become a popular prescription for chronic weight management, but many users report digestive side effects—diarrhea being one of the most common. Understanding why this happens, how to manage it, and when it might be time to consider a medication change can help you stay on track with your health goals without unnecessary discomfort.
Wegovy belongs to a class of drugs called GLP-1 receptor agonists. These medications mimic a natural hormone (glucagon-like peptide-1) that helps regulate appetite and blood sugar. Here's how GLP-1 activity can lead to diarrhea:
Slowed gastric emptying
GLP-1 receptor agonists delay the time it takes for food to move from your stomach into the small intestine. This can sometimes disrupt normal digestive rhythms, leading to loose stools.
Increased intestinal fluid secretion
Semaglutide can promote fluid secretion in the small intestine. An excess of fluid in the bowel makes stool less formed.
Altered gut motility
By affecting nerve signals in the gut, GLP-1 drugs can speed up or irregularize contractions in the intestines, resulting in diarrhea.
Changes in gut microbiota
Early research suggests that GLP-1 receptor agonists may shift the balance of bacteria in your gut, which could influence stool consistency.
Not everyone on Wegovy will develop diarrhea. Factors that may increase your risk include:
If you've just started Wegovy or recently increased your dose, mild diarrhea is often temporary. Try these practical steps to reduce symptoms:
Follow a BLAND-FOOD approach:
Limit fat and fiber extremes:
Stay hydrated:
Slow dose titration
Injection timing
Loperamide or bismuth subsalicylate
Probiotics
Soluble fiber
Most episodes of Wegovy-related diarrhea are mild and self-limited. Monitor for these warning signs, which warrant prompt medical attention:
If you experience any of these symptoms, it's important to seek help. You can get personalized insights about your digestive symptoms by using a Medically approved LLM Symptom Checker Chat Bot to understand what might be causing your discomfort and when you should see a doctor.
Deciding whether to stay on Wegovy or move to another treatment depends on several factors:
Symptom severity and duration
Impact on weight-loss goals
Alternative options
Personal preference and lifestyle
Always discuss medication changes with your healthcare provider. They will weigh the risks and benefits based on your unique situation.
Keep a symptom diary
Stay in close contact with your care team
Focus on overall gut health
Be patient with dose escalations
Plan for travel or events
While minor diarrhea can often be managed at home, never ignore severe or prolonged symptoms. If you suspect dehydration, significant abdominal pain, or any life-threatening concerns, speak to a doctor immediately or call emergency services.
Navigating Wegovy's digestive side effects doesn't have to derail your health journey. With the right strategies—diet tweaks, gradual dose changes, and timely medical advice—you can keep diarrhea in check. Remember, if common-sense measures aren't enough or you're facing red-flag symptoms, reach out to your healthcare provider for personalized guidance.
(References)
* Karam Z, Younes S, Al-Qudimat Y, et al. Efficacy and Safety of Once-Weekly Semaglutide for Weight Management in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis. *JAMA Netw Open*. 2023;6(7):e2324901. Published 2023 Jul 5. doi:10.1001/jamanetworkopen.2023.24901
* Andres A, et al. Gastrointestinal Side Effects of Glucagon-like Peptide-1 Receptor Agonists: A Systematic Review and Meta-Analysis. *Obesity (Silver Spring)*. 2021;29(5):940-951. doi:10.1002/oby.23151
* Davies MJ, et al. Management of gastrointestinal side effects with glucagon-like peptide-1 receptor agonists: a practical guide. *Diabetes Metab Res Rev*. 2020;36(5):e3305. doi:10.1002/dmrr.3305
* Rubino F, et al. Effect of semaglutide on gastrointestinal symptoms and quality of life in patients with obesity: A post hoc analysis of the STEP 1-3 trials. *Obesity (Silver Spring)*. 2023;31(5):1257-1267. doi:10.1002/oby.23724
* Dhillon S, et al. Semaglutide for weight loss: a review of the current evidence. *Pharmacol Res Perspect*. 2022;10(2):e00949. doi:10.1002/prp2.949
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.